← Back to Clinical Trials
Recruiting NCT00792155

NCT00792155 Polycystic Kidney Disease Data Repository

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT00792155
Status Recruiting
Phase
Sponsor The Rogosin Institute
Condition Polycystic Kidney Disease
Study Type OBSERVATIONAL
Enrollment 1,000 participants
Start Date 2002-11
Primary Completion 2030-12

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 1,000 participants in total. It began in 2002-11 with a primary completion date of 2030-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Autosomal dominant polycystic kidney disease (PKD) is the most common inherited kidney disease, affecting more than 400,000 people in the U.S. and 5 million people worldwide. PKD is the 4th most common cause of kidney failure requiring dialysis and/or transplantation. Over half of all PKD patients develop kidney failure by age 60 years, although age of onset of kidney disease varies widely, even among members of the same family. Despite the fact this is a relatively common problem, relatively few patients have been studied for a sufficient period of time to fully understand how patients are affected over the course of their lifetime. The reason for creating this repository is to collect information about PKD so that the investigators may fully understand its complications, including high blood pressure, heart attack, and stroke. This information may also aid in the development of improved treatment strategies.

Eligibility Criteria

Inclusion Criteria: * Any person, age 18 or older, with previously diagnosed ADPKD is eligible to participate. Exclusion Criteria: * Inability to provide informed consent.

Contact & Investigator

Central Contact

Jon Blumenfeld, MD

✉ jdblume@nyp.org

📞 212-746-1553

Principal Investigator

Jon Blumenfeld, MD

PRINCIPAL INVESTIGATOR

The Rogosin Institute

Frequently Asked Questions

Who can join the NCT00792155 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Polycystic Kidney Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT00792155 currently recruiting?

Yes, NCT00792155 is actively recruiting participants. Contact the research team at jdblume@nyp.org for enrollment information.

Where is the NCT00792155 trial being conducted?

This trial is being conducted at New York, United States.

Who is sponsoring the NCT00792155 clinical trial?

NCT00792155 is sponsored by The Rogosin Institute. The principal investigator is Jon Blumenfeld, MD at The Rogosin Institute. The trial plans to enroll 1,000 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology